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Overexpression of disease-associated 9-O-acetylated sialoglycoproteins (9-O-AcSGPs) on peripheral blood
mononuclear cells (PBMC) of visceral leishmaniasis (VL) patients (PBMCVL) compared to their levels of
expression in healthy individuals has been demonstrated using a lectin, achatinin-H, with specificity toward
9-O-acetylated sialic acid derivatives 2-6 linkage with subterminal N-acetylgalactosamine (9-O-AcSA2-
6GalNAc). The decreased presence of disease-associated 9-O-AcSGPs on different immune cells of parasito-
logically cured individuals after successful treatment relative to the levels in patients with active VL prior to
treatment was demonstrated. However, their contributory role as immunomodulatory determinants on PBM-
CVL remained unexplored. Accordingly, 9-O-AcSGPs on PBMCVL were sensitized with achatinin-H, leading to
their enhanced proliferation compared to that observed with different known mitogens or parasite antigen.
This lymphoproliferative response was characterized by evaluation of the TH1/TH2 response by intracellular
staining and enzyme-linked immunosorbent assay for secreted cytokines, and the results were corroborated by
their genetic expression. Sensitized PBMCVL evidenced a mixed TH1/TH2 cellular response with a predomi-
nance of the TH1 response, indicating the ability of 9-O-AcSGPs to modulate the host cell toward a favorable
response. Interestingly, the humoral and cellular responses showed a good correlation. Further, high levels of
anti-9-O-AcSGP antibodies with an order of distribution of immunoglobulin M (IgM) > IgG1  IgG3 >
IgG4 > IgG2 > IgE could be explained by a mixed TH1/TH2 response. A good correlation of enhanced
9-O-AcSGPs with both the cell-mediated (r  0.98) and humoral (r  0.99) response was observed. In
summary, it may be concluded that sensitization of 9-O-AcSGPs on PBMCVL may provide a basis for the
modulation of the host’s immune response by their controlled expression, leading to a beneficial immune
response and influencing the disease pathology.
Sialic acids comprise a family of 9-carbon carboxylated
acidic monosaccharides that exist as either N- or O-substituted
forms (35, 36, 47–49). Sialic acid is commonly referred to as
N-acetyl neuraminic acid, or Neu5Ac (36). A diverse range of
almost 50 known derivatives of sialic acids has been docu-
mented. Among them, 7-, 8-, and 9-O-acetylated derivatives
(O-AcSA) are essential constituents of the cell membrane well
noted for their involvement in different physiological and
pathological processes (12, 19, 36).
Human visceral leishmaniasis (VL), or kala-azar, caused by
the intracellular protozoan parasite Leishmania donovani, is
endemic in 62 countries and is a major public health threat,
with an estimated 200 million people worldwide at risk (13,
16). The severity of VL pathogenesis is predominantly marked
by immunosuppression that is manifested by decreased levels
of gamma interferon (IFN-) and interleukin-12 (IL-12), along
with an increased TH2 response evidenced by elevated levels
of IL-4 and IL-10 (3, 18, 33, 52). The active disease state also
induces the production of high levels of specific antibody sub-
classes whose involvement in conferring host protection has yet
to be proved (34). More importantly, increasing drug resis-
tance of the leishmanial parasites has worsened the scenario
(45). Therefore, an urgent need exists for the search for newer
determinants which would in turn affect the disease’s pathol-
ogy through balanced beneficial immunomodulation of the
host.
In this regard, we have demonstrated the presence of dis-
ease-associated 9-O-acetylated sialoglycoproteins (9-O-AcSGPs)
on different immune cells of peripheral blood mononuclear
cells (PBMC) of patients with active VL (PBMCVL) using a
lectin, achatinin-H, having preferential affinity toward terminal
9-O-AcSA derivatives 2-6 linked to subterminal N-acetyl-
galactosamine, 9-O-AcSA2-6GalNAc (4, 22, 37, 38). How-
ever, their role in modulating the immune response and
thereby regulating the clinical course of the disease remained
unaddressed. Accordingly, the present investigation focused
on (i) the differential expression of 9-O-AcSGPs on immune
cells of patients compared to their expression on PBMC of
patients after successful treatment (posttreatment; PBMCPT);
(ii) the lymphoproliferative response upon sensitization of dis-
ease-associated 9-O-AcSGPs on PBMCVL; and subsequently,
(iii) the characterization of a mixed TH1/TH2 response upon
sensitization of 9-O-AcSGPs. Since cytokines regulate anti-
body isotype switching during B-cell development (17, 24, 32,
34, 43), a study of the subclass distribution of the antibodies
was performed to unravel the processes involved in the diver-
gence of the immune responses during disease. In this regard,
we also provide evidence for a good correlation between TH1-
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cell-mediated and humoral responses as evaluated by measur-
ing anti-O-AcSGP-specific antibody subclass expression.
Taken together, the results of this in vitro study unravel the
immunomodulatory role of 9-O-AcSGPs and their influence
on the disease’s pathology, which may provide a basis for
triggering a beneficial immune response by their controlled
expression in the active disease state.
MATERIALS AND METHODS
Study subjects. The study involved patients with clinically confirmed VL (n 
25) at the time of diagnosis at the School of Tropical Medicine, Kolkata, India.
Diagnosis of VL was based on microscopic demonstration of Leishmania amas-
tigotes in splenic aspirates, according to WHO recommendations (51). The
diagnosis was further confirmed by three in-house techniques, namely, (i) para-
site antigen enzyme-linked immunosorbent assay (ELISA) (9) for estimation of
antileishmanial serology, (ii) erythrocyte binding (11) and hemagglutination as-
says for quantification of the increased presence of linkage-specific 9-O-AcSGPs,
and (iii) ELISA for detection of anti-9-O-AcSGP antibodies (10). The healthy
volunteers (n  25) were individuals with negative results for antileishmanial
serology, erythrocyte binding assay, and anti-9-O-AcSGP antibody titer. Patients
with active VL were treated with sodium antimony gluconate (20 mg/kg of body
weight/day for 3 months) or amphotericin B (1 mg/kg/per day for 1 month),
respectively. After completing chemotherapy, the patients were monitored for
the disappearance of the clinical symptoms and were also evaluated by the
described in-house techniques. The institutional ethical committee approved the
study. Blood was collected after obtaining informed consent of the donors,
patients, or in the case of minors, from the parent or guardian.
Isolation of PBMC. PBMC were separated using density gradient centrifuga-
tion at 400  g for 30 min by layering peripheral blood over Ficoll-Hypaque (1:1;
Amersham Pharmacia, Uppsala, Sweden). The layer of PBMCVL was washed
twice in phosphate-buffered saline (0.02 M, pH 7.2) and resuspended in RPMI
1640 medium supplemented with penicillin (100 U/ml), streptomycin (100 g/
ml), and 10% heat-inactivated fetal calf serum (medium A). Prior to the assays,
the cellular viability was checked by using trypan blue exclusion, which revealed
95% viability. In parallel, PBMCPT and PBMC from healthy donors (PBMCH)
were isolated similarly.
Probe. The lectin achatinin-H was affinity purified using bovine submandibular
mucin (BSM), known to contain a high percentage of 9-O-AcSAs, as an affinity
matrix (27, 37–38). The carbohydrate binding specificity of achatinin-H was
checked by hemagglutination and hemagglutination inhibition assays using sev-
eral mono- and disaccharides, as well as several sialoglycoproteins, as inhibitory
reagents (30, 38). Achatinin-H was conjugated with fluorescein isothiocyanate
(FITC) and used for flow cytometry (8).
Detection of 9-O-AcSGPs on PBMCVL subsets by flow cytometry. Different
monoclonal antibodies such as anti-CD3, CD13, CD16, and CD19 antibodies
used for the assay were from Pharmingen (San Diego, CA). PBMC (1  106/100
l) were suspended in medium A and stained on ice for 1 h with FITC–
achatinin-H and phycoerythrin (PE)–anti-CD monoclonal antibodies along with
appropriate isotype controls. The cells were then washed, fixed in paraformal-
dehyde (1%), acquired on a FACSCalibur flow cytometer, and analyzed using
CellQuest software (Becton, Dickinson, and Co., Mountain View, CA). The
specificity of achatinin-H interaction with 9-O-AcSGPs on PBMCVL was con-
firmed after incubation of the cells with 9-O-acetyl hemagglutinin esterase of
influenza C virus for 1 h at 37°C, as described elsewhere (8, 50). In parallel,
PBMCPT and PBMCH were similarly processed.
Determination of the specificity of 9-O-AcSGPs by inhibition ELISA. 9-O-
AcSGPs on PBMCVL were affinity purified using achatinin-H as an affinity matrix
as described elsewhere (22). The binding of 9-O-AcSGPs to achatinin-H was
detected by incubation with anti-9-O-AcSGP antibodies (1 g) that were affinity
purified from sera of patients with active VL overnight at 4°C (10). The binding
specificity of purified 9-O-AcSGPs was confirmed by inhibition ELISA (30).
Several inhibitors, including synthetic Me--Neu5,9Ac2, BSM, which has a large
amount of linkage-specific 9-O-AcSA (38), de-O-acetylated BSM, desialylated
BSM, sheep submandibular mucin, human chorionic gonadotrophin, fetuin, and
1-acid glycoprotein having no O-AcSAs, were used. The binding of 9-O-AcS-
GPs to immobilized achatinin-H (1 g/100 l/well) in Tris-buffered saline (TBS;
0.05 M, pH 7.2) at 4°C was performed in the presence of these inhibitors to
compare their capacity to inhibit this interaction. Affinity-purified disease-asso-
ciated 9-O-AcSGPs (1 g) in 50 l of TBS containing 30 mM Ca2 (TBS-Ca)
and bovine serum albumin (2%) were initially incubated for 30 min at 4°C with
each inhibitor (50 l, 10 to 60 mM) separately. After subsequent blocking and
washing, the mixture (100 l) was added to achatinin-H-coated wells and incu-
bated overnight at 4°C, and the antigen–anti-O-AcSGP antibody complex was
subsequently measured colorimetrically using horseradish peroxidase (HRP)-
conjugated protein A (diluted 1:10,000; Cappel, St. Louis, MO) and azino-bis-
thio-sulfonic acid (Sigma, St. Louis, MO) with recording at 405 nm in an ELISA
reader.
In vitro lymphoproliferation assay. The lymphoproliferation assay was per-
formed with achatinin-H (0.1 to 10 g) as described elsewhere (40). In brief,
PBMCVL (1  105 cells/ml) from patients before and after treatment were
cultured in triplicate in medium A, in the presence or absence of achatinin-H, in
96-well microtiter plates for 0 to 96 h at 37°C in an atmosphere of 5% CO2. All
the parameters of the assay, such as cell concentration and time kinetics, were
varied while keeping others constant to optimize the culture conditions. In
parallel, a lymphoproliferation assay was carried out using known T- and B-cell
mitogens, such as concanavalin A (ConA) and phytohemagglutinin (PHA). Ad-
ditionally, crude parasite antigen (9) was used under identical conditions.
Cultures were pulsed with [3H]thymidine (1 Ci/well) for 18 h, and [3H]thy-
midine uptake was measured. The dose for maximal proliferation of each sample
was determined from the graph obtained by plotting the incorporated radioac-
tivity against the dose of mitogen. Results were also expressed as the stimulation
index (SI), which was calculated as follows: SI  mean counts per minute in
stimulated culture/mean counts per minute in unstimulated culture.
The lymphoproliferation assay of PBMCVL upon sensitization of 9-O-AcSGPs
with achatinin-H was also performed by incubating the lectin (0.10 g) with BSM
at the optimal inhibitory concentration (0.05 mol/liter) for 1 h at 37°C, and the
cells were subsequently cultured for 72 h to assess the specificity. Cells were
de-O-acetylated by esterase treatment (8, 50). In parallel, de-O-acetylated cells
in the presence and absence of achatinin-H and BSM served as different controls.
PBMCH were processed similarly for comparison.
Additionally, viable cells after lymphoproliferation were assessed by methyl-
thiazoltetrazolium (MTT) assay. In brief, MTT solution (100 g/50 l) was
added to each well separately and further incubated for 4 h at 37°C. The
mitochondrial enzyme succinate dehydrogenase cleaves the tetrazolium salt,
MTT, into a blue-colored product (formazan) that occurs as crystals (15). The
crystals of formazan were dissolved in dimethyl sulfoxide (450 l), and the
absorbance at 570 nm was recorded in a spectrophotometer as a quantitative
measure of cell proliferation (or viability). In parallel, under identical conditions,
viable cells were assessed by the conventional trypan blue dye exclusion assay.
Cytokine ELISA. Following the culture of PBMC in the presence or absence
of achatinin-H, the cell-free culture supernatants were collected at the indicated
time points (0 to 96 h) used in the lymphoproliferation assay and stored at70°C
for the detection of released cytokines, namely, IFN-, IL-10, IL-12, IL-2, and
tumor necrosis factor (TNF-). The respective cytokines were quantified using
commercially available ELISA kits according to the manufacturer’s instructions
(OptEIA kit for humans; Pharmingen, San Diego, CA). Briefly, microtiter wells
were coated with individual cytokine antibodies, and after subsequent nonspe-
cific blocking with phosphate-buffered saline–bovine serum albumin, cytokine
standards or culture supernatants were added to designated wells and incubated
for 1 h at 25°C. To determine the concentration of cytokines in culture super-
natants, standard curves were constructed using recombinant cytokines, and
cytokine concentrations in test samples were determined from the corresponding
concentration values from the standard curve.
Intracellular cytokine analysis by flow cytometry. Intracellular cytokines of the
PBMCVL resulting from sensitization of 9-O-AcSGPs by achatinin-H were de-
tected. Cells were cultured with or without achatinin-H for 72 h, washed, and
incubated with brefeldin A (10 g/ml) for a further 4 h at 37°C. Washed cells
were permeabilized using fluorescence-activated cell sorter permeabilizing solu-
tion (500 l) for 6 to 8 min, stained with PE-conjugated cytokine-specific anti-
bodies for 30 min at 4°C in the dark, processed, and analyzed by flow cytometry.
The cells were initially gated for the presence of cell surface 9-O-AcSGPs by
using FITC–achatinin-H and analyzed for intracellular cytokines. In parallel,
PBMCPT and PBMCH were processed similarly. Unsensitized PBMC served as
negative controls.
Reverse transcription-PCR studies. RNA (1 g) isolated from PBMCVL after
subsequent sensitization with achatinin-H (0.1 g) by Trizol was reverse tran-
scribed using a poly(dT) oligonucleotide and SuperScript II reverse transcriptase
(20). The cDNA was amplified using specific primers as follows: IFN- forward,
5	-TCTGCATCGTTTTGGGTTCT-3	, and reverse, 5	-CAGCTTTTCGAAGT
CATCTC-3	 (product size, 300 bp); IL-12p40 forward, 5	-CCAAGAACTTGC
AGCAGCTGAAG-3	, and reverse, 5	-TGGGTCTATTCCGTTGTGTC-3	
(product size, 360 bp); IL-10 forward, 5	-AGATCTCCGAGATGCCTTTCA-3	,
and reverse, 5	-TTTCGTATCTTCATTGTCATGTA-3	 (product size, 408 bp);
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IL-4 forward, 5	-CGGCAACTTTGACCACGGACACAAGTGCG-3	, and re-
verse, 5	-AGGACACTTCCTTCGGTTGGTCTCATGCA-3	 (product size, 244
bp); and TNF- forward, 5	-GAGTGACAAGCCTGTAGCCCATGTTGTAG
CA-3	, and reverse, 5	-GCAATGATCCCAAAGTAGACCTGCCCAGACT-3	
(product size, 444 bp). Each PCR cycle consisted of denaturation at 94°C for 30 s,
annealing at 55°C for 45 s, and extension at 72°C for 1 min using specific primers
for cytokines in a Perkin-Elmer DNA thermal cycler. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), used as control, was PCR amplified using
5	-ATGGGGAAGGTGAAGGTCGG-3	 for the forward primer and 5	-GGGT
GCTAAGCAGTTGGT-3	 for the reverse primer (product size, 540 bp). An
agarose gel (1%) stained with ethidium bromide was used to analyze the prod-
ucts of PCR (10 l) after visualization under UV light. Quantification of the
comparative intensities of the bands for the respective cytokines were scored by
densitometry using Quantity One software.
Subclass ELISA. The levels of different anti-O-AcSGP-specific antibody sub-
classes in VL patients before and after treatment were determined by subclass
ELISA. BSM in Tris buffer (0.05 M, pH 7.2) served as the coating antigen (1
g/100 l/well). After nonspecific blocking, serum samples (diluted 1:50, 100
l/well) were added and incubated overnight at 4°C. The wells were incubated
separately with HRP-conjugated mouse anti-human immunoglobulin G1 (IgG1),
IgG2, IgG3, IgG4, and IgM (1:5,000), respectively, to determine the levels of
subclasses of anti-O-AcSGP-specific antibodies. Next, the wells were washed
with TBS (0.05 M, pH 7.2) containing 0.1% Tween 20 and incubated with
HRP-conjugated anti-mouse IgG, and the antigen-antibody complex was colo-
rimetrically measured on an ELISA reader at 405 nm, using azino-bis-thiosul-
fonic acid as the substrate.
For determination of levels of anti-O-AcSGP-specific IgE, patients’ sera (1:10,
100 l/well) were preincubated with Sepharose-protein G beads (25% vol/vol)
for 18 h at 4°C (2, 41). The mixture was centrifuged at 2,000 g for 5 min at 4°C,
and the supernatant (100 l) was added to the wells and incubated. After
washing, HRP–anti-human IgE (1:2,500; Calbiochem, CA) was added and the
antigen-antibody complex was measured as described previously.
Statistical analysis. Results are expressed as the means 
 standard deviations
(SD) for individual sets of experiments. Statistical analysis was performed using
Graph-Pad Prism statistics software (Graph-Pad Software, San Diego, CA).
Student’s unpaired or paired t tests were used. Reported values are two tailed,
and P values lower than 0.05 were considered statistically significant. The Spear-
man correlation test was used for the comparison of independent variables.
RESULTS
Study subjects. Among patients with VL, 18 of 25 were
male. The average and the median ages were comparable for
patients with VL and healthy controls. The clinical and labo-
ratory features of the patients on admission and after treat-
ment are summarized in Table 1. The response to sodium
antimony gluconate or amphotericin B therapy was timely.
Leucopenia and decreased hemoglobin were observed in pa-
tients with active VL who were subsequently monitored during
the course of treatment. The splenic aspirate smears of all the
patients after treatment showed an absence of parasites (i.e.,
L. donovani bodies), and they were therefore clinically defined
as parasitologically cured.
At the time of diagnosis, the sera of patients with active VL
had high levels of parasite-specific antibodies compared to the
levels in individuals after treatment (means 
 SD at an optical
density of 405 nm [OD405], 1.15
 0.65 versus 0.202
 0.71), as
determined by parasite-specific ELISA using immobilized
crude parasite antigen (9). The 9-O-AcSGPs were exclusively
detected on erythrocytes of these patients, as determined by
flow cytometry using FITC–achatinin-H (68%
 5.15%), eryth-
rocyte binding ELISA (mean 
 SD at OD405, 1.18 
 0.61), and
hemagglutination assay (mean 
 standard error of the mean,
145.70 
 42.21) using achatinin-H as an analytical probe (11,
27, 38). The erythrocytes from patients after treatment and
from healthy individuals completely lacked these sialogly-
cotopes.
Status of 9-O-AcSGPs on immune cells of VL patients be-
fore and after successful chemotherapy. To determine the
contributory role of 9-O-AcSGPs on PBMCVL in immuno-
modulation, their status on different immune cells was moni-
tored before and after chemotherapy. Interestingly, two-color
flow cytometry demonstrated decreased FITC–achatinin-H
binding to the surface of T, B, and NK cells and monocytes of
PBMCPT, reflecting low levels of 9-O-AcSGPs, comparable to
the levels in PBMCH, and indicating their restricted distribu-
tion in the active disease state that could be potentially impor-
tant for immunomodulation (Table 2).
The binding specificity of 9-O-AcSGPs on PBMCVL was
determined by an inhibition ELISA. Initially, achatinin-H was
used as the coating antigen. The binding of purified 9-O-AcS-
GPs by achatinin-H was inhibited with increasing concentra-
tions of synthetic Me--Neu5,9Ac2. This binding was maxi-
TABLE 1. Clinical features of the study populationa
Feature
Value for group
VL patients
Healthy
controlsWith active
disease Posttreatment
Age (yr) 25.2 
 10.75 26 
 11.05 30.5 
 8.65
Median (range) 22 (6–46) 19 (7–41) 31 (25–52)
Sex ratio (male:female) 18:7 18:7 16:9
Body wt (kg) 39.52 
 11.36 41.00 
 10.18 60 
 6.25
BMIb 17 
 0.65 20.5 
 1.05 22 
 1.15
Duration of illness
(mo)
4.25 
 2.25 NA NA
Karnofsky scorec 73.15 
 2.25 83.50 
 3.16 95.02 
 5.72
Splenic amastigote
scored
4.25 
 0.27 0 0
Spleen size (cm) 8.15 
 1.12 4.01 
 1.02 Not palpable
White blood cell count
(103/mm3)
3.53 
 0.81 4.55 
 1.42 8.2 
 2.11
Red blood cell count
(106/l)
1.75 
 1.21 3.15 
 0.88 5.25 
 1.71
Hemoglobin concn
(g/dl)
5.22 
 0.42 9.44 
 0.15 11.5 
 2.21
Mean cell hemoglobin
concn (g/dl)
30 
 1.22 32 
 1.12 35 
 1.86
Hematocrit (%) 33 
 1.17 39 
 1.15 52 
 3.05
Parasite antigen
ELISAe
1.15 
 0.65 0.202 
 0.71 0.121 
 0.31
Erythrocyte binding
assayf
1.18 
 0.61 0.185 
 0.81 0.102 
 0.43
9-O-AcSA-positive
erythrocytes (%)f
68 
 5.15 6.50 
 1.25 ND
a Data are given as the mean 
 SD unless otherwise indicated. NA, not
applicable; ND, not detectable.
b Body mass index (BMI) is weight in kilograms divided by square of height in
meters; normal BMI is 18.5 to 24.9.
c The Karnofsky performance scale is as follows: 100, able to carry on normal
activity and no special care is needed, with no complaints and no evidence of
disease; 90, able to carry on normal activity, with minor signs or symptoms of
disease; 80, normal activity with effort, with some signs or symptoms of disease;
70, unable to work but able to live at home and care for most personal needs,
with various amounts of assistance needed.
d 5, 10 to 100 parasites/field; 4, 1 to 10 parasites/field; 3, 1 to 10 para-
sites/10 fields; 2, 1 to 10 parasites/100 fields; 1, 1 to 10 parasites/1,000 fields;
0, no parasites or 1 to 10 parasites/1,000 fields.
e Antileishmanial serology was estimated using immobilized crude parasite
antigen as described elsewhere (20).
f Increased presence of linkage-specific 9-O-AcSGPs on erythrocytes of pa-
tients with active VL was quantified by erythrocyte-binding assay and flow cy-
tometry (21).
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mally inhibited at 60 mM of Me--Neu5,9Ac2. In parallel,
BSM, an O-acetylated sialoglycoprotein with high 9-O-AcSA
content, showed the greatest inhibition of binding of purified
9-O-AcSGPs with achatinin-H. Several sialoglycoproteins with
no O-AcSA, namely de-O-acetylated BSM, sheep submandib-
ular mucin, fetuin, human chorionic gonadotrophin, and 1-
acid glycoprotein, showed no binding.
Sensitization of 9-O-AcSGPs on PBMCVL induces their en-
hanced proliferation. With a view to addressing the role of
9-O-AcSGPs in immunomodulation, their involvement in lym-
phoproliferation of PBMCVL after sensitization in the pres-
ence of different doses of achatinin-H for 72 h or without
sensitization was measured. Maximal lymphoproliferation of
PBMCVL was achieved with 0.1 g of achatinin-H at 72 h as
determined by both the radiometric (Fig. 1A) and colorimetric
MTT (Fig. 1B) assays. VL is typically associated with leucope-
nia accompanied by immunosuppression; the response of
PBMCVL to known T- and B-cell mitogens (ConA and PHA)
and parasite antigen was, as expected, much lower than that
evidenced with achatinin-H (Fig. 1C). Significantly, the SI of
PBMCVL was 28 after sensitization of 9-O-AcSGPs for 72 h
(Fig. 1D). Enhanced proliferation provided the first indication
of 9-O-AcSGPs as one of the important determinants on
PBMCVL responsible for triggering immune modulation.
PBMCVL preincubated with the optimum inhibitory concen-
tration of BSM and cultured in the presence of achatinin-H
(0.1 g) demonstrated an absence of lymphoproliferation (Fig.
1E). In parallel, PBMCVL treated with O-acetyl esterase and
cultured similarly in the presence of achatinin-H demonstrated
an absence of proliferation (Fig. 1E). BSM alone, in the ab-
sence of achatinin-H and under similar conditions, demon-
strated no proliferative response, indicating that the lympho-
proliferation was through 9-O-AcSGPs. In contrast, PBMCPT
and PBMCH showed negligible proliferation even at a very
high dose of achatinin-H (10 g), due to a minimal presence of
9-O-AcSGPs and their lesser affinity toward achatinin-H, indi-
cating that this response was specifically associated with the
clinical status of the disease.
Lymphoproliferative response on sensitization of 9-O-AcSGPs
on PBMCVL induces enhanced cytokine secretion. As immu-
nity to leishmania infection is cell mediated and mainly con-
trolled by parasite killing due to activation of host cells, we
analyzed the cytokines secreted by the PBMCVL following
sensitization of disease-associated 9-O-AcSGPs at various time
points as an index of activation and regulation of the immune
response.
The secretion of both TH1 and TH2 cytokines in the super-
natants of proliferated PBMCVL showed a time-dependent
response that was maximal at 72 h. Interestingly, sensitization
of 9-O-AcSGPs demonstrated a mixed TH1/TH2 type with a
predominance of the TH1 response (Fig. 2, Table 3).
Specifically, in the 9-O-AcSGP-sensitized PBMCVL culture
supernatants, the levels of the signature TH1 cytokine IFN-,
which is instrumental in activating the host’s leishmanicidal
activity (28), were considerably higher than in unsensitized
PBMCVL, with a mean 
 SD of 162 
 4.21 pg/ml versus 35 

3.51 pg/ml (Fig. 2A). Another cytokine, IL-12, also plays an
important role in regulating the onset and continuation of the
TH1 response (46) that confers protection against leishmani-
asis. Sensitized PBMCVL demonstrated a 12.67-fold-higher
level of IL-12 than unsensitized PBMCVL (Fig. 2B). Similarly,
the level of IL-2 was also higher (Fig. 2C), indicating the
predominance of the TH1 response mediated by sensitization
of 9-O-AcSGPs in the active disease condition of VL.
The level of the TH2 cytokine IL-10, an important regulator
of immunosuppression (14, 34), was slightly higher in 9-O-
AcSGP-sensitized PBMCVL than in the unsensitized controls,
the mean 
 SD being 116 
 6.50 pg/ml versus 95 
 5.6 pg/ml
(Fig. 2D). IL-4, a cytokine of the TH2 response, also evidenced
a small increase after sensitization of PBMCVL (Fig. 2E), in-
dicating that although the response was mixed, it predomi-
nantly favored the increase of TH1-specific cytokines.
More importantly, TNF-, one of the essential fundamental
cytokines involved in the host response in confronting micro-
bial infection (31), was drastically elevated in the culture su-
pernatants of sensitized PBMCVL compared to its level in
unsensitized controls (Fig. 2F), further indicating that proper
balanced modulation of this sialoglycotope leads to a beneficial
host response.
The predominance of TH1 cytokines after sensitization of
9-O-AcSGPs on PBMCVL was further confirmed by the results
of intracellular staining of cytokines using flow cytometry (Fig.
3), which were consistent with the pattern of secreted cyto-
kines. After sensitization, the percentages of 9-O-AcSA-posi-
tive cells that stained for IFN- and IL-12 were two- and
fivefold higher, respectively, than in unsensitized PBMCVL
(Fig. 3). On the other hand, in the 9-O-AcSA-positive cells
stained for TH2 cytokines, the levels of IL-10 and IL-4 were
lower, suggesting that these disease-associated 9-O-AcSGPs
could be successfully modulated toward a host-protective ben-
eficial response.
Under similar conditions, PBMCPT and PBMCH with neg-
ligible levels of 9-O-AcSGPs demonstrated insignificant levels
of secreted cytokines and an almost complete absence of dou-
ble-positive cells, suggesting that these unique 9-O-acetylated
sialoglycoproteins are one of the potential determinants respon-
sible for disease-specific host immune modulation (Table 3).
To further confirm our results, we studied the genetic ex-
TABLE 2. Comparative profiles of 9-O-AcSA in patients with
active VL and posttreatment
Cell type
% of 9-O-AcSA-positive cells froma
VL patients
Healthy
controlsWith active
diseasec Posttreatment
PBMC 84.82 
 3.55b 7 
 3.15 6.5 
 2.5
T 60.23 
 4.68b 10.01 
 5.01 8.22 
 3.55
B 19.14 
 0.35 6.34 
 0.76 5.14 
 1.11
NK 11.26 
 3.23 4.06 
 2.13 4.16 
 1.32
Monocyte 47.72 
 0.76b 7.52 
 2.16 6.02 
 1.46
a Data are given as the mean 
 SD. To determine the distribution of 9-O-
AcSA on cells of different lineages in patients with active VL and posttreatment
(n  25), double-color flow cytometric analysis was performed. PBMC were
incubated with FITC-achatinin-H and respective PE-conjugated lineage-specific
monoclonal antibodies and analyzed as described in Materials and Methods.
b Significantly different from healthy control subjects (P  0.05).
c The experiment was performed with the same group of active VL patients
used for the previous study, as described elsewhere (22). After successful che-
motherapy, paired samples from this group of patients were used for comparison.
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pression of the cytokines after subsequent sensitization of 9-O-
AcSGPs on PBMCVL for 0 to 96 h (Fig. 4). Cytokine tran-
scripts of both IFN- and IL-12 demonstrated maximal
overexpression at 72 h as shown by densitometry scanning (Fig.
4). In contrast, the levels of of TH2 cytokines IL-10 and IL-4
released after sensitization of PBMCVL were lower than the
levels of TH1 cytokines. As expected, unsensitized cells evi-
denced basal levels of cytokine synthesis.
Enhanced levels of anti-O-AcSGP antibodies in patients
with active VL and their reduction after successful chemother-
apy. In order to correlate the induced cellular responses with
the humoral, serum samples from patients with active VL
before and after treatment and from healthy control subjects
were tested for the distribution of anti-O-AcSGP-specific an-
tibody subclasses.
All the anti-O-AcSGP antibody subclasses were elevated in
the sera of VL patients (Fig. 5). The level of anti-O-AcSGP
IgM (Fig. 5A) was maximal in patients with active VL (mean

SD at OD405, 1.25 
 0.07). The levels of anti-O-AcSGP IgG1
(Fig. 5B) and IgG3 (Fig. 5D) were also significantly higher,
with the means 
 SD at OD405 being 1.05 
 0.06 and 1.03 

0.07, respectively, possibly due to the predominance of the
induced TH1 response in the milieu. The levels of anti-O-
AcSGP IgG2 (Fig. 5C), IgG4 (Fig. 5E), and IgE (Fig. 5F) were
also increased. Taken together, our data indicate that the sub-
class order of levels of anti-O-AcSGP antibodies in VL patients
at the time of diagnosis is IgM IgG1 IgG3 IgG4 IgG2
IgE, revealing a mixed TH1/TH2 response. The enhanced anti-
O-AcSGP antibodies showed a good correlation (r  0.99) with
the overexpression of 9-O-AcSGPs on PBMCVL.
The levels of all the anti-O-AcSGP antibody subclasses
declined in the sera of successfully treated individuals and
FIG. 1. Enhanced lymphoproliferation of PBMCVL upon sensitization of disease-associated 9-O-AcSGPs by achatinin-H. (A) SI as demon-
strated by the radiometric method. PBMCVL (1  10
5 cells/ml) before (f) and after () sensitization were cultured separately with achatinin-H
(0.1 to 12 g) for 72 h at 37°C in an atmosphere of 5% CO2. Cultures were pulsed with [
3H]thymidine (1 Ci/well) for 18 h, and its uptake was
measured. Results are expressed as the SI as described in Materials and Methods. The data show a profile representative of the results for 25
patients. The points represent the means 
 SD of the results for triplicate determinations. (B) Maximal lymphoproliferation demonstrated by
colorimetric MTT assay. PBMCVL (n  25) before (f) and after () treatment were sensitized through 9-O-AcSGPs by using different
concentrations of achatinin-H (0.1 to 10 g) for 72 h at 37°C in an atmosphere of 5% CO2 and assessed by MTT assay. The formazan crystals that
formed were dissolved in dimethyl sulfoxide (450 l), and the absorbance at 570 nm was recorded with a spectrophotometer as a quantitative
measure of cell proliferation (or viability). In parallel, PBMCH (n  25) (Œ) were processed similarly. The points represent the means 
 SD of
the results for triplicate determinations. (C) Comparison of levels of lymphoproliferation induced by different mitogens versus the level induced
by achatinin-H. PBMCVL (1  10
5 cells/ml; n  25) were sensitized with two well-known mitogens, namely, PHA and ConA, and with crude
parasite antigen and achatinin-H (0.1 g) under identical assay conditions. Subsequently, the viability of the cells was assessed by MTT as described
for panel B. Unsensitized PBMCVL served as controls for the assay. The points represent the means 
 SD the results for triplicate determinations.
, P value of 0.01 for the observed lymphoproliferation with achatinin-H versus that in unsensitized controls; #, P value of 0.05 versus the
lymphoproliferation with other mitogens (PHA and ConA). (D) SI of PBMCVL sensitized with achatinin-H (0.1 g) before (f) and after ()
treatment plotted against different culture time points (0 to 96 h). The data show a profile representative of the results for 25 patients. Each point
represents the mean 
 SD of the results for triplicate determinations. (E) 9-O-AcSGPs serve as an important glycotope for lymphoproliferation
after sensitization with achatinin-H. PBMCVL were cultured in the absence () or presence of achatinin-H (0.1 g) before (f) and after
preincubation with BSM () and were de-O-acetylated ( O-acetyl esterase), and their viability was assessed by MTT assay as described in
Materials and Methods. The data show a profile representative of the results for 25 patients. The points represent the means 
 SD of the results
for triplicate determinations. , present; , absent.
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were comparable to the levels evidenced in healthy donors
(Fig. 5).
DISCUSSION
Immunosuppression is a predominant feature associated
with VL (29, 33), which presents as a decreased TH1 response
along with a simultaneous elevation of the TH2 response. The
considerable decline in the expression of disease-associated
9-O-AcSGPs on PBMCPT compared to the level on PBMCVL
instigated us to explore their contribution as immunomodula-
tory determinants. Importantly, sensitization of these mole-
cules resulted in enhanced lymphoproliferation of PBMCVL
that led to the production of a mixed TH1/TH2 response with
a predominance of TH1 cytokines. A good correlation of this
cellular response with the humoral response suggested the
probable beneficial role of 9-O-AcSGPs in modulating the host
immune response, depending upon the clinical status.
The search for immunomodulatory determinants as effective
vaccine candidates is an ever-expanding area of research. A
number of parasite antigens have been shown to possess the
capacity to modulate the immune response of the host. The
crude parasite antigen has been documented to produce a
mixed TH1/TH2 response in PBMCVL (16, 23, 34). Notable
among them is kinetoplast membrane protein 11 of L. dono-
vani, which stimulated both the TH1/TH2 response and the
production of recombinant papLe22 of L. infantum that trig-
gered PBMCVL to liberate IL-10 (7, 44). Although the induc-
tion of a mixed TH1/TH2 response has been associated with
therapy in patients with active VL, the elicitation of a response
with a predominance of TH1 by immunomodulatory determi-
nants from either parasite or host is certainly preferable (34).
FIG. 2. Enhanced secretion of TH1 cytokines by 9-O-AcSGP-sensitized PBMCVL. PBMCVL were cultured after sensitization in the absence (f)
or presence () of achatinin-H (0.1 g) for 0 to 96 h. The concentration of the released cytokines, namely, IFN- (A), IL-12 (B), IL-2 (C), IL-10
(D), IL-4 (E), and TNF- (F), in the culture supernatant was detected by ELISA as described in Materials and Methods. In parallel, PBMCPT were
sensitized in the absence (Œ) or presence (‚) of achatinin-H under identical conditions, where unsensitized cells served as controls. The data show
a profile representative of the results for VL patients (n  25). The points represent the means 
 SD of the results for triplicate sets.
TABLE 3. Comparison of levels of TH1/TH2 cytokines in culture supernatants of 9-O-AcSGP-sensitized and unsensitized PBMCa
Cytokine
Amt (pg/ml) of cytokine released by:
PBMCVL PBMCPT PBMCH
Unsensitized Sensitizedb Unsensitized Sensitized Unsensitized Sensitized
IL-12 9 
 3.20 114 
 4.25 77.55 
 6.24 80 
 2.64 43 
 6.20 44 
 5.55
IFN- 35 
 3.51 162 
 4.21 96 
 5.51 99 
 2.51 32 
 1.75 36 
 5.4
IL-2 6.22 
 2.45 67.50 
 2.81 55 
 3.5 57.51 
 3 65 
 4.30 64.45 
 4
IL-10 95 
 5.6 116 
 6.50 34.55 
 8.25 37.85 
 3 55 
 5 59.25 
 3
IL-4 85 
 3.15 96 
 3.51 15.20 
 2.16 19 
 1.21 10.15 
 0.91 9.33 
 2
TNF- 25.25 
 3.21 175 
 4.53 56.55 
 4.12 67 
 3.81 70 
 2.81 72 
 3.65
a Data are expressed as the means 
 SD of triplicate sets and are representative of the results for 25 patients and healthy individuals. The detection of released
cytokines in the cell-free culture supernatants following culture before and after 72 h of sensitization was performed using commercially available ELISA kits according
to the manufacturer’s instructions. Briefly, ELISA plates were coated with individual cytokine antibodies and blocked, after which cytokine standards or culture
supernatants were added to the wells for quantification as described in Materials and Methods.
b All values were significantly different from those for healthy control subjects (P  0.05) and from those for VL patients posttreatment (P  0.01).
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However, the role of O-AcSGPs in immunomodulation of the host’s
immune response is a relatively unexplored area in the disease
biology of VL. Previous studies by our group, using the pref-
erential binding specificity of achatinin-H, have shown the ex-
pression on the cell surface of promastigotes of two specific
9-O-AcSGPs with molecular masses of 123 and 109 kDa (8,
27). Concomitantly, enhanced anti-9-O-AcSGP-specific anti-
body responses against these parasite-specific sialoglycopro-
teins have been witnessed as a part of the host defense mech-
anism (5, 6, 10, 39). Furthermore, these antibodies, as reported
earlier, are leishmanicidal in activity; that is, they are capable
of triggering the classical complement pathway, thereby caus-
ing Leishmania cell death (5). Alternatively, several other 9-O-
AcSGPs have been documented on immune cells (65, 56, and
19 kDa) and erythrocytes (112, 107, 103, 57, 51, and 48 kDa) of
VL patients (4, 11, 22). Since the alteration of sialic acid
expression (via the alteration of enzymes responsible for sialic
acid metabolism) has been well documented as a disease-in-
duced phenomenon (26, 48, 49), the induction of these 9-O-
AcSGPs on the host cells of patients with active VL is possibly
a result of parasitic infection. Importantly, previous studies
have demonstrated that each of these 9-O-AcSGP molecules is
different from the others at the protein level, as revealed in
isoelectric-focusing studies by the presence of discrete bands
indicating their molecular heterogeneity, even though they
are all alike in having 9-O-AcSA on their terminal surface
(22). Thus, anti-9-O-AcSGP antibodies driven by the 9-O-
AcSGPs present on the parasites recognize the disease-
associated 9-O-AcSGPs on PBMCVL via recognition of the
terminal 9-O-AcSA. Taking into consideration the impor-
tance of 9-O-AcSGPs in VL, their role as determinants
promoting immunomodulation by pronounced lymphopro-
liferation has been investigated.
Our results, therefore, provide a clue to the involvement of
enhanced sialylation on the immune cells of active VL patients
(Table 2). The decline of 9-O-AcSGPs on T and B lympho-
cytes, as well as monocytes, in patients after successful chemo-
therapy was comparable to the levels in healthy donors and
definitely suggested a probable link between this sialogly-
cotope and the course of the disease. The occurrence of en-
hanced sialylation on the surface of immune cells of VL pa-
tients hints at the presence of differential levels of four main
enzymes, O-acetyltransferase, sialyltransferases, sialidase, and
O-acetylesterases, that are responsible for regulating the me-
tabolism of sialoglycoproteins or, more precisely, sialic acids
(26, 42). Although limited molecular information about these
enzymes during disease conditions has decelerated their explo-
ration, studies pertaining to the causes of the altered expres-
sion of sialic acids are in progress.
The elevated levels of 9-O-AcSGP on all cells of PBMCVL
indicate their probable involvement in enhanced proliferation.
This was clearly demonstrated by sensitization of the newly
induced 9-O-AcSA2-6GalNAc sialoglycotopes on PBMCVL
(Fig. 1). The increase in the lymphoproliferative response of
PBMCVL through disease-associated 9-O-AcSGPs reflected
their biologically active nature during disease presentation.
The sensitization of PBMCVL after preincubation with BSM or
de-O-acetylation demonstrated an absence of lymphoprolif-
eration, reconfirming the inevitable involvement of O-AcSAs
in this interaction (Fig. 1E). In contrast, the lack of prolifera-
tion of PBMCPT and PBMCH under similar conditions further
confirmed the disease-associated sensitization of 9-O-AcSGPs,
FIG. 4. Enhanced mRNA expression of the TH1 cytokines in sen-
sitized PBMCVL. The levels of different cytokines along with GAPDH
(housekeeping gene) were evaluated by reverse transcription of RNA
(0.1 g) extracted from achatinin-H (0.1 g) sensitized PBMCVL (n 
10) at different time points (0 to 96 h) as described in Materials and
Methods. The mRNA expression of unsensitized cells served as the
control. The values were compared by densitometric scores and are
represented as the increase in band intensity compared with the ex-
pression of GAPDH at the respective time points.
FIG. 3. Representative profiles of cell-mediated responses upon
sensitization of 9-O-AcSGPs on PBMCVL. 9-O-AcSGPs of PBMCVL
(n  15) were sensitized with achatinin-H (0.1 g) for 72 h and
cultured at 37°C in an atmosphere of 5% CO2. Subsequently, the cells
were stained for intracellular cytokines with PE-conjugated, cytokine-
specific antibodies for 30 min at 4°C in the dark, processed, and
analyzed by flow cytometry using CellQuest software. Lymphocytes
were gated on the basis of their light scatter properties and were
checked for the presence of cell surface 9-O-AcSGPs using FITC–
achatinin-H to determine the percentages of 9-O-AcSA-positive cells
that were stained for the respective intracellular cytokines. In parallel,
PBMCPT were processed similarly. Unsensitized PBMC served as neg-
ative controls.
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indicating their ability to generate an immunomodulatory re-
sponse that contributes to VL pathogenesis. Interestingly, the
much-lower lymphoproliferative response with known T- and
B-cell mitogens and parasite antigen further confirmed the
importance of 9-O-AcSGPs as potent immunomodulatory
molecules influencing the pathology of VL.
Cytokines are the most important determinants that play a
role in the defense mechanism of the host against infection.
Because the pathology of VL is associated with the suppression
of cell-mediated immunity (23, 33), we analyzed at the extra-
cellular, intracellular, and genetic levels the pattern of cyto-
kines resulting from the lymphoproliferative response upon
sensitization of disease-associated 9-O-AcSGPs on PBMCVL.
The IFN--mediated innate and cellular responses that are
instrumental in triggering leishmanicidal responses by acti-
vated macrophages determine the disease status and are also
prerequisites for protection (28, 29, 31, 34). Elevated levels of
IL-4 and IL-10, the signature TH2 cytokines, correlate with the
active disease state, whereas the level of IFN-, along with the
level of IL-12, increases in patients after successful chemother-
apy, signifying the restoration of the suppressed TH1 response
(34). A 12.67-fold increase in the amount of IL-12 secreted by
sensitized PBMCVL was probably sufficient to modulate a level
of production of IFN- that was 4.6-fold-higher than the level
in unsensitized controls (Fig. 2). Therefore, sensitization of
9-O-AcSGPs appears to play an important role in modulating
the immune response toward a TH1 bias. Moreover, the fact
that the amount of IL-2 in the culture supernatant of sensitized
PBMCVL was larger than the amount in the unsensitized con-
trols reconfirmed the predominance of the TH1 response as a
result of the proliferation induced through sensitization of
9-O-AcSGPs (Table 3). Additionally, the increased secretion
of both IL-10 and IL-4 by sensitized PBMCVL suggests that
this interaction was also capable of generating a TH2 response
that was essentially lower than the TH1 response. This trend of
cytokine secretion was evidenced at the intracellular level, at
which assays demonstrated an increased percentage of 9-O-
AcSA-positive cells that stained for the TH1 cytokines after
sensitization (Fig. 3). The results were consistent with the
increased mRNA expression of IFN-, IL-12, and TNF- (Fig.
4), indicating the potential of 9-O-AcSGPs in driving PBMCVL
toward a mixed TH1/TH2 response, with a bias toward the
TH1 response, through successful modulation. Importantly,
increased levels of TNF- in sensitized PBMCVL reflected the
increased expression of proinflammatory cytokines upon sen-
sitization, revealing the importance of 9-O-AcSGPs in VL
pathogenesis. Taken together, these findings indicate that 9-O-
AcSGPs appear to be important molecules contributing to the
pathogenesis of VL by regulation of the immune responses in
favor of the host.
The overall profile of the cellular responses is indispensable
in defining the disease status of VL patients before and after
chemotherapy (23). However, the disease also presents
marked levels of parasite-specific antibodies in the sera of VL
patients, which have diagnostic relevance as they happen to be
the first signs of the infection (9, 25, 39, 41). Hence, a proper
correlation of the cellular and humoral responses is key to
understanding the disease pathogenesis. Therefore, the ob-
served good correlation of the cell-mediated and humoral re-
sponses evidenced by increased subclass distribution of anti-
O-AcSGP-specific antibodies confirmed the induced mixed
cytokine response (Fig. 5) and reflected the highly immuno-
genic nature of 9-O-AcSGPs. It is known that IFN- probably
upregulates isotypes IgG1 and IgG3 (1, 32) and that the TH2
cytokines stimulate the production of IgG4 and IgE (17, 24).
The increased levels of anti-9-O-AcSGP IgG1 and IgG3
showed the predominant TH1 response elicited upon sensiti-
zation of 9-O-AcSGPs. Furthermore, the increase in IgE and
IgG4 levels in patients with active VL in comparison to the
levels in individuals after treatment could be explained by the
FIG. 5. Distribution of anti-O-AcSGP-specific antibody subclasses in VL patients before and after treatment. The levels of anti-O-AcSGP-
specific IgM (A), IgG1 (B), IgG2 (C), IgG3 (D), IgG4 (E), and IgE (F) in VL patients before treatment (n  25) were determined by subclass
ELISA as described in Materials and Methods. The sera of individuals after treatment (n  25) were tested similarly. Horizontal lines indicate
mean values. , P value of 0.01 for difference from results for successfully treated individuals; #, P value of 0.05, and , P value of 0.01 for
difference from results for healthy controls.
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activation of the TH2 response, supporting the mixed response
generated subsequent to sensitization. Hence, a good correla-
tion of enhanced 9-O-AcSGPs with both the cell-mediated (r
0.98) and humoral (r  0.99) response was observed, further
signifying their importance as immunomodulatory determi-
nants.
Taken together, our results conclusively prove the consider-
able reduction in expression of 9-O-AcSGPs on different im-
mune cells and of their specific antibody isotypes in the sera of
parasitologically cured VL patients compared to the levels in
patients with active VL. Additionally, we have demonstrated
that these molecules can be sensitized, resulting in a cascade of
immunomodulatory effects generating an elevated immune re-
sponse with a TH1 bias. This kind of sensitization of O-acety-
lated sialoglycotopes via specific ligands hints at their biologi-
cal role in determining immune responses that decided the
course of the disease. In agreement with the observed finding,
the anti-9-O-AcSGPs present in VL patients’ sera may act as
ligands for 9-O-AcSGPs on PBMCVL, which could possibly be
instrumental in causing such effects in the host. In-depth stud-
ies to reveal the causative molecules responsible for such im-
munomodulation are ongoing. With the development of newer
sialoglycotherapeutic strategies (21), the controlled expression
of these molecules may be exploited to pave the way for gen-
erating beneficial effects in VL patients.
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